FDA Approves Expanded Indication for Gilead’s Biktarvy to Treat People with HIV with Suppressed…
Gilead Sciences, Inc. announced the U.S. Food and Drug Administration (FDA) approved a new, expanded indication for Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir…
Read More...
Read More...